Imagion Biosystems Market Herald Interview

We recently announced plans to conduct our first in-human study for MagSense in Australia later this year.

In this Market Herald interview, watch IBX CEO Bob Proulx describe why Australia’s favourable clinical environment and the ability to expand the study to include MRI make Australia the ideal setting for this upcoming study.

Watch the interview: